Lessening the Impact of Fatigue in inflammatory rheumatic diseases: a randomised Trial (LIFT)
Duration: 01 August 2016 - 31 January 2021
Funder: Versus Arthritis (formerly Arthritis Research UK)
Chief investigator: Professor Gary Macfarlane
Co-chief investigator: Dr Neil Basu (University of Glasgow)
Study Co-ordinator: Dr Eva Bachmair
Fatigue is pervasive, disabling and challenging to manage across all inflammatory rheumatic diseases. Therapies designed to improve physical activity and ‘talking’ treatments, which positively help patients change the way they think and behave, are both helpful in reducing the burden of the fatigue. However, few patients have access to these treatments in the NHS. We also don't understand how these treatments work or which patients are most likely to benefit. This information could help to improve future treatments making them more efficient.
- Background and study methods
With LIFT, we want to find out if a talking therapy (CBA) or personalised exercise programme (PEP) is better than usual care alone in helping you to reduce the impact of fatigue.
We recruited 368 adults aged 18 and over with inflammatory rheumatic diseases who experience significant fatigue from our six study centres in Aberdeen, Dundee, Edinburgh, Glasgow, Newcastle and Stoke-Midlands. People who were suitable to take part in the study were sent a letter by their direct care team. Recruitment started in August 2017 and concluded in September 2019.
Participants received either a talking therapy plus usual care, a personalised exercise programme plus usual care or usual care alone.
Some participants who received either talking therapy or the exercise programme will now be followed up and invited to take part in an optional interview with researchers to discuss their experiences with the treatment after completing the programme. In addition, some participants with rheumatoid arthritis will be invited to take part in an optional sub-study involving two additional MRI brain scans.
More information about LIFT is available, here.
Some participants who received either talking therapy or the exercise programme were followed up and invited to take part in an optional interview with researchers to discuss their experiences with the treatment after completing the programme. In addition, some participants with rheumatoid arthritis are currently being invited to take part in an optional sub-study involving two additional MRI brain scans.
- Study team
- Kathryn R Martin - Co-investigator
- Paul McNamee - Co-investigator
- Eva-Maria Bachmair - Study co-ordinator
- Graeme MacLennan - CHaRT team
- John Norrie - Co-investigator (University of Edinburgh)
- Alison Wearden - Co-investigator (University of Manchester)
- Karina Lovell - Co-investigator (University of Manchester)
- Richard Emsley -Co-investigator (Kings College London)
- Lorna Paul - Co-investigator (Glasgow Caledonian University)
- Stuart Gray - Co-investigator (University of Glasgow)
- Stefan Siebert - Co-investigator (University of Glasgow)
- Sarah Hewlett - Co-investigator (University of West of England)
- Emma Dures - Co-investigator (University of West of England)
- Study sites
- Contact us
LIFT Trial Office
Epidemiology Group, University of Aberdeen
Health Sciences Building, Foresterhill
Aberdeen Scotland AB25 2ZD